Group 1 - Zhejiang Apac Pharmaceutical Co., Ltd. announced the completion of the transfer of control to Xinghao Holdings, marking the end of a three-month control change process [1] - The transfer involved a share transfer at a price of 8.26 yuan per share, totaling 900 million yuan for a 14.61% stake, representing a 45.68% premium over the pre-suspension price of 5.67 yuan [1] - Apac Pharmaceutical plans to raise up to 700 million yuan through a private placement to fund new drug research and development, further consolidating Xinghao Holdings' control [1] Group 2 - Xinghao Holdings has signed a technology development contract with Beijing Sunshine Nuohuo Pharmaceutical Research Co., Ltd. for the domestic rights transfer of the innovative drug STC008, targeting late-stage non-small cell lung cancer [2] - The change in control signifies a new era for Apac Pharmaceutical under the leadership of Qiu Zhongxun, who is expected to integrate digital ecosystems with the company's R&D capabilities [2] - The market anticipates that Qiu Zhongxun will lead the revival and new achievements of this established pharmaceutical company [2]

Core Viewpoint - The control change at Asia-Pacific Pharmaceutical (亚太药业) has been completed, with Xinghao Holdings becoming the new controlling shareholder, holding a total of 14.61% voting rights, marking a significant transition in the company's leadership and strategic direction [1][2] Group 1: Control Change Details - Xinghao Holdings acquired 14.61% of the voting rights through a combination of direct shareholding and the transfer of voting rights from a related party [1] - The share transfer involved a total transaction amount of 900 million yuan at a price of 8.26 yuan per share, representing a premium of 45.68% over the pre-suspension price of 5.67 yuan per share [1] Group 2: Future Plans and Strategic Direction - Following the share issuance, Xinghao Holdings is expected to hold 22.38% of the company's shares, further solidifying its control [2] - The new actual controller, Qiu Zhongxun, is a prominent figure in the pharmaceutical industry, which is anticipated to enhance the company's innovation and development capabilities [2] - Asia-Pacific Pharmaceutical plans to transition from traditional chemical generics to improved new drugs and innovative drug development, supported by a fundraising effort of up to 700 million yuan for research projects [1][2]